Skip to main content

Advertisement

Log in

Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Introduction

HSRT directed to large surgical beds in patients with resected brain metastases improves local control while sparing patients the toxicity associated with whole brain radiation. We review our institutional series to determine factors predictive of local failure.

Methods

In a total of 39 consecutive patients with brain metastases treated from August 2011 to August 2016, 43 surgical beds were treated with HSRT in three or five fractions. All treatments were completed on a robotic radiosurgery platform using the 6D Skull tracking system. Volumetric MRIs from before and after surgery were used for radiation planning. A 2-mm PTV margin was used around the contoured surgical bed and resection margins; these were reviewed by the radiation oncologist and neurosurgeon. Lower total doses were prescribed based on proximity to critical structures or if prior radiation treatments were given. Local control in this study is defined as no volumetric MRI evidence of recurrence of tumor within the high dose radiation volume. Statistics were calculated using JMP Pro v13.

Results

Of the 43 surgical beds analyzed, 23 were from NSCLC, 5 were from breast, 4 from melanoma, 5 from esophagus, and 1 each from SCLC, sarcoma, colon, renal, rectal, and unknown primary. Ten were treated with three fractions with median dose 24 Gy and 33 were treated with five fractions with median dose 27.5 Gy using an every other day fractionation. There were no reported grade 3 or higher toxicities. Median follow up was 212 days after completion of radiation. 10 (23%) surgical beds developed local failure with a median time to failure of 148 days. All but three patients developed new brain metastases outside of the treated field and were treated with stereotactic radiosurgery, whole brain radiation and/or chemotherapy. Five patients (13%) developed leptomeningeal disease. With a median follow up of 226 days, 30 Gy/5 fx was associated with the best local control (93%) with only 1 local failure. A lower total dose in five fractions (ie 27.5 or 25 Gy) had a local control rate of 70%. For three fraction SBRT, local control was 100% using a dose of 27 Gy in three fractions (follow up was > 600 days) and 71% if 24 Gy in three fractions was used. A higher total biologically equivalent dose (BED10) was statistically significant for improved local control (p = 0.04) with a threshold BED10 ≥ 48 associated with better local control.

Conclusions

HSRT after surgical resection for brain metastasis is well tolerated and has improved local control with BED10 ≥ 48 (30 Gy/5 fx and 27 Gy/3 fx). Additional study is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Patchell RA, Regine WF (2003) The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat 2(2):111–115

    Article  PubMed  Google Scholar 

  2. Gaspar LE, Mehta MP, Patchell RA et al (2010) The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):17–32

    Article  PubMed  Google Scholar 

  3. Kazda T, Jancalek R, Pospisil P et al (2014) Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol 9:139

    Article  PubMed  PubMed Central  Google Scholar 

  4. Brown PD, Pugh S, Laack NN et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429–1437

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Gondi V, Pugh SL, Tome WA et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32(34):3810–3816

    Article  PubMed  PubMed Central  Google Scholar 

  6. Shaw E, Scott C, Souhami L et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47(2):291–298

    Article  PubMed  CAS  Google Scholar 

  7. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD (2006) Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64(3):898–903

    Article  PubMed  Google Scholar 

  8. Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387–395

    Article  PubMed  Google Scholar 

  9. Korytko T, Radivoyevitch T, Colussi V et al (2006) 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys 64(2):419–424

    Article  PubMed  Google Scholar 

  10. Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77(4):996–1001

    Article  PubMed  Google Scholar 

  11. Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mahajan A, Ahmed S, Mcaleer MF et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048

    Article  PubMed  PubMed Central  Google Scholar 

  13. Keller A, Dore M, Cebula H et al (2017) Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases. Int J Radiat Oncol Biol Phys 99(5):1179–1189

    Article  PubMed  Google Scholar 

  14. Minniti G, D’angelillo RM, Scaringi C et al (2014) Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol 117(2):295–301

    Article  PubMed  CAS  Google Scholar 

  15. Garcia LM, Wilkins DE, Raaphorst GP (2007) Alpha/beta ratio: a dose range dependence study. Int J Radiat Oncol Biol Phys 67(2):587–593

    Article  PubMed  Google Scholar 

  16. Fowler JF (2009) Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling. Int J Radiat Oncol Biol Phys 73(5):1532–1537

    Article  PubMed  Google Scholar 

  17. Kwon AK, Dibiase SJ, Wang B, Hughes SL, Milcarek B, Zhu Y (2009) Hypofractionated stereotactic radiotherapy for the treatment of brain metastases. Cancer 115(4):890–898

    Article  PubMed  Google Scholar 

  18. Jeong WJ, Park JH, Lee EJ, Kim JH, Kim CJ, Cho YH (2015) Efficacy and safety of fractionated stereotactic radiosurgery for large brain metastases. J Korean Neurosurg Soc 58(3):217–224

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Ahmed KA, Sarangkasiri S, Chinnaiyan P et al (2016) Outcomes following hypofractionated stereotactic radiotherapy in the management of brain metastases. Am J Clin Oncol 39(4):379–383

    Article  PubMed  Google Scholar 

  20. Matsuyama T, Kogo K, Oya N (2013) Clinical outcomes of biological effective dose-based fractionated stereotactic radiation therapy for metastatic brain tumors from non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85(4):984–990

    Article  PubMed  Google Scholar 

  21. Lischalk JW, Oermann E, Collins SP et al (2015) Five-fraction stereotactic radiosurgery (SRS) for single inoperable high-risk non-small cell lung cancer (NSCLC) brain metastases. Radiat Oncol 10:216

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ishihara T, Yamada K, Harada A et al (2016) Hypofractionated stereotactic radiotherapy for brain metastases from lung cancer: evaluation of indications and predictors of local control. Strahlenther Onkol 192(6):386–393

    Article  PubMed  Google Scholar 

  23. Steinmann D, Maertens B, Janssen S et al (2012) Hypofractionated stereotactic radiotherapy (hfSRT) after tumour resection of a single brain metastasis: report of a single-centre individualized treatment approach. J Cancer Res Clin Oncol 138:1523–1529

    Article  PubMed  Google Scholar 

  24. Doré M, Martin S, Delpon G, Clément K, Campion L, Thillays F (2017) Stereotactic radiotherapy following surgery for brain metastasis: predictive factors for local control and radionecrosis. Cancer Radiother 21(1):4–9

    Article  PubMed  Google Scholar 

  25. Rajakesari S, Arvold ND, Jimenez RB et al (2014) Local control after fractionated stereotactic radiation therapy for brain metastases. J Neurooncol 120:339–346

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aryavarta M. S. Kumar.

Ethics declarations

Conflict of interest

The authors declare they have no conflict of interest relating to this manuscript.

Ethical approval

This manuscript is based on a retrospective review on an IRB approved study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, A.M.S., Miller, J., Hoffer, S.A. et al. Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10. J Neurooncol 139, 449–454 (2018). https://doi.org/10.1007/s11060-018-2885-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-018-2885-6

Keywords

Navigation